Stuart D. Shumway, Ph.D.

Affiliations: 
2001 University of Wisconsin, Madison, Madison, WI 
Area:
Molecular Biology, Cell Biology, Immunology
Google:
"Stuart Shumway"

Parents

Sign in to add mentor
Shigeki Miyamoto grad student 2001 UW Madison
 (The constitutive proteolysis of IkappaBalpha in B-lymphocytes maintains NF-kappaB activity.)
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

O'Neil J, Benita Y, Feldman I, et al. (2016) An unbiased oncology compound screen to identify novel combination strategies. Molecular Cancer Therapeutics
Pokorny JL, Calligaris D, Gupta SK, et al. (2015) The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 1916-24
Guertin AD, Li J, Liu Y, et al. (2013) Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy. Molecular Cancer Therapeutics. 12: 1442-52
Russell MR, Levin K, Rader J, et al. (2013) Combination therapy targeting the Chk1 and Wee1 kinases shows therapeutic efficacy in neuroblastoma. Cancer Research. 73: 776-84
Guertin AD, Martin MM, Roberts B, et al. (2012) Unique functions of CHK1 and WEE1 underlie synergistic anti-tumor activity upon pharmacologic inhibition. Cancer Cell International. 12: 45
Aarts M, Sharpe R, Garcia-Murillas I, et al. (2012) Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1. Cancer Discovery. 2: 524-39
Sarcar B, Kahali S, Prabhu AH, et al. (2011) Targeting radiation-induced G(2) checkpoint activation with the Wee-1 inhibitor MK-1775 in glioblastoma cell lines. Molecular Cancer Therapeutics. 10: 2405-14
Rajeshkumar NV, De Oliveira E, Ottenhof N, et al. (2011) MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 2799-806
Nagashima K, Shumway SD, Sathyanarayanan S, et al. (2011) Genetic and pharmacological inhibition of PDK1 in cancer cells: characterization of a selective allosteric kinase inhibitor. The Journal of Biological Chemistry. 286: 6433-48
Shumway SD, Xiong Y. (2006) Twice primed: cyclin E is phosphorylated and isomerized before being ubiquitinated. Molecular Cell. 23: 149-50
See more...